CClinicalTrials.gg
CompletedNCT01918280FERTIPRESERVEUpdated Dec 19, 2025

Fertility Preservation in Cases of Klinefelter Syndrome.

An interventional study of Seminal analyses and testicular biopsy in Klinefelter Syndrome, sponsored by Hospices Civils de Lyon. Completed at 4 sites in France. Open to male participants aged 15 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Non-randomized
Ages
15 Years to 55 Years
Sex
Male
01

Study summary

Klinefelter Syndrome (KS) is the most common sex chromosomal abnormalities (1/600 newborn males), and is characterized by a hypergonadism hypogonadism. Until few years ago, mostly non-mosaic KS was considered as a model of a complete male infertility although few KS (4-8%) have an oligospermia. Recent studies in adult with non-mosaic KS reported the possibility of sperm retrieval by testicular biopsy (TESE) in around 50% cases and more than some pregnancies have been obtained after TESE with Intracytoplasmic Sperm Injection (ICSI). Since 1997, more than one hundred births are described.

As some studies shown a decrease of successful sperm retrieval with the increasing of age, we plan to compare the potential of sperm retrieval between two groups "adult" (23-55 years) and "young" after the onset of puberty (15-22 years). The study will be performed by searching spermatozoa on two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.

02

Conditions studied

  • Klinefelter Syndrome

Keywords

  • Klinefelter Syndrome
  • Azoospermia
  • Seminal analyses
  • Testicular biopsy
03

Who can participate

Ages eligible
15 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • Klinefelter Syndrome with 47,XXY non-mosaic
  • Androgenotherapy stopped since more than 6 months

Exclusion criteria

Exclusion Criteria:

  • Antecedent of Radiotherapy or chemotherapy
  • Psychological trouble
  • Treatment interfering with spermatogenesis
  • Androgenotherapy non stopped
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    Young group

    Patient aged 15-22 years for seminal analyses and testicular biopsy

    Procedure: Seminal analyses and testicular biopsy

  • Other
    Adult group

    Patient aged 23-55 years for seminal analyses and testicular biopsy

    Procedure: Seminal analyses and testicular biopsy

Interventions

  • ProcedureSeminal analyses and testicular biopsy

    Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.

05

What researchers measure

Primary outcomes

  1. TEsticular Sperm Extraction (TESE)

    Improvement of sperm retrieval rate by Testicular Sperm extraction (TESE) in the "Young" group compare to "Adult" group.

    Time frame: 15 months

Secondary outcomes

  1. Androgenotherapy

    Influence of antecedent of androgenotherapy before Testicular Sperm extraction (TESE) : treatment or not, duration of treatment

    Time frame: 15 months

  2. Prognosis factors

    Identification of prognosis factors of sperm retrieval (by TESE) in the two groups "Young" and "Adult"

    Time frame: 15 months

  3. Histopathologist analyses

    Histopathologist analyses of testicular biopsy in the two groups "Young" and "Adult". In the 2 groups, comparison of cases with and without sperm.

    Time frame: 15 months

06

Study locations

4 sites
  • Service de Biologie de la Reproduction - CECOS - Groupe Hospitalier Pellegrin
    Bordeaux, 33076, France
  • Service d'Endocrinologie Moléculaire et Maladies Rares, Centre de Biologie Est, Hospices Civils de Lyon
    Bron, 69677, France
  • Service de Biologie de la Reproduction - Hôpital de la Conception
    Marseille, 13385, France
  • Groupe de Médecine de la Reproduction - CECOS Midi-Pyrénées - Hôpital Paule de Viguier)
    Toulouse, 31059, France
07

References and documents

Publications

  • Plotton I, Giscard d'Estaing S, Cuzin B, Brosse A, Benchaib M, Lornage J, Ecochard R, Dijoud F, Lejeune H; FERTIPRESERVE group. Preliminary results of a prospective study of testicular sperm extraction in young versus adult patients with nonmosaic 47,XXY Klinefelter syndrome. J Clin Endocrinol Metab. 2015 Mar;100(3):961-7. doi: 10.1210/jc.2014-3083. Epub 2014 Nov 25. PubMed 25423570 ↗
  • Renault L, Labrune E, Giscard d'Estaing S, Cuzin B, Lapoirie M, Benchaib M, Lornage J, Soignon G, de Souza A, Dijoud F, Fraison E, Pral-Chatillon L, Bordes A, Sanlaville D, Schluth-Bolard C, Salle B, Ecochard R, Lejeune H, Plotton I. Delaying testicular sperm extraction in 47,XXY Klinefelter patients does not impair the sperm retrieval rate, and AMH levels are higher when TESE is positive. Hum Reprod. 2022 Oct 31;37(11):2518-2531. doi: 10.1093/humrep/deac203. PubMed 36112034 ↗
08

Registry details

Key details

Study ID
NCT01918280
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Aug 7, 2013
Start date
Sep 20, 2010
Primary completion
Sep 17, 2018
Completion
Sep 17, 2018
Last update
Dec 19, 2025

Study contacts

Ingrid PLOTTON, MD
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion